Caladrius Biosciences to Present at Multiple Upcoming November Conferences

BASKING RIDGE, N.J., Nov. 02, 2015 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius”), a company combining a leading cell therapy service provider with a therapeutics pipeline including a Phase 3 clinical program in immuno-oncology and a portfolio of earlier clinical phase projects in immune modulation and ischemic repair, announces today that the Company’s leadership, experts and related research investigators will present at three conferences in November.

SITC 2015 30th Anniversary Annual Meeting & Associated Programs

  • Website: http://www.sitcancer.org/2015/
  • Venue: Gaylord National Hotel & Convention Center, National Harbor, Maryland
  • Date and Time: Thursday, November 5, 2015, 4:00 PM ET

Session 1

  • Presenter: Robert Dillman, MD, Vice President, Oncology
  • Poster Topic: Superiority of Dendritic Cell Vaccine vs Tumor Cell Vaccine: Survival by stratification subsets in MACVAC randomized phase II trial of patient-specific vaccines utilizing antigens from autologous melanoma tumor cell lines

Session 2

  • Presenter: Gabriel Nistor, MD, Vice President, Research
  • Poster Topic: Functional Properties of Patient-Derived Melanoma Cancer Stem Cells

American Heart Association Scientific Sessions 2015

Session 1

  • Date and Time: Monday, November 9, 2015, 9:00 AM ET
  • Session Moderator: Douglas Losordo, MD, Senior Vice President, Clinical, Medical and Regulatory Affairs and Chief Medical Officer
  • Topic: Biological Therapies in Peripheral Artery Disease: Current Standards and Concepts

Session 2

  • Date and Time: Monday, November 9, 2015, 9:24 AM ET
  • Presenter: Douglas Losordo, MD, Senior Vice President, Clinical, Medical and Regulatory Affairs and Chief Medical Officer
  • Topic: CD34 Positive Cells in PAD: Current Evidence

Session 3

  • Date and Time: Monday, November 9, 2015, 4:15 PM ET
  • Presenter: Arshed A. Quyyumi, MD, Professor of Medicine at Emory University, Lead Principal Investigator of PreSERVE-AMI study
  • Topic: Infused CD34 Cell Dose, Not Bone Marrow CD34+ Cell Content, Improves Clinical Outcomes and LVEF in Patients with Left Ventricular Dysfunction Post STEMI: Results of the PreSERVE-AMI trial

Society for Melanoma Research 2015 Congress

  • Website: http://www.melanomacongress.com/
  • Venue: San Francisco Marriott Marquis, San Francisco, California
  • Date and Time: Wednesday, November 18, 2015, 7:30 PM ET

Session 1

  • Presenter: Robert Dillman, MD, Vice President, Oncology
  • Poster Topic: Superiority in a Randomized Trial of Patient-Specific Dendritic Cell/Tumor Cell Vaccines vs Tumor Cell Vaccines in Subsets Defined by Disease Stage, Tumor Measurability, and Lactate Dehydrogenase (LDH) level

Session 2

  • Presenter: Gabriel Nistor, MD, Vice President, Research
  • Poster Topic: Mechanism of Action of CLBS20, A Patient-Specific Immunotherapy Targeting Metastatic Melanoma

About Caladrius Biosciences

Caladrius Biosciences, Inc. is among the first of a new breed of immunotherapy companies with proven expertise and unique experience in cell process optimization, development, and manufacturing. Caladrius combines a leading cell therapy service provider with a development pipeline including late-stage clinical programs based on a proprietary platform technology for immuno-oncology, as well as additional platform technologies for immunomodulation and ischemic repair. This integrated approach supports the industry in bringing significant life-improving medical treatments to market. For more information, visit www.caladrius.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company’s business strategy, the Company’s ability to develop and grow its business, the successful development of cellular therapies with respect to the Company’s research and development and clinical evaluation efforts in connection with the Company’s Immuno-oncology Program, Immune Modulation Program, Ischemic Repair Program and other cell therapies, the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry, and the performance and planned expansion of the Company’s wholly-owned subsidiary and its center of excellence for cell therapy process development, engineering and manufacturing, PCT, as well as its efforts to expand its capabilities into the cell therapy tools market. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the “Risk Factors” described in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 2, 2015, and in the Company’s other periodic filings with the SEC. The Company’s further development is highly dependent on future medical and research developments and market acceptance, which is outside of its control.

CONTACT: Investors:
LHA
Anne Marie Fields
Senior vice President
Phone: +1-212-838-3777
Email: afields@lhai.com

Media: 
Caladrius Biosciences, Inc.
Eric Powers
Manager of Communications and Marketing
Phone: +1-212-584-4173
Email: epowers@caladrius.com